Various studies support the view that analogs of luteinizing hormone-releasing hormone (LH- des-Gly10-[D-Ser(tBu)6]LH-RH ethylamide (buserelin) had no effect. The antagonists SB-29 and SB-30 also inhibited the rate of cell growth, as measured by cell number, while the LH-RH agonist buserelin had no significant effect. These results support the concept that these new LH-RH antagonists can directly inhibit the growth of human mammary tumors and thus might be suitable for the treatment of breast cancer.
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Chronic administration of potent agonists of luteinizing hormone-releasing hormone (LH-RH) results in the inhibition of pituitary and gonadal function (1, 2) and creates a state of sex-steroid deficiency. Consequently, agonists of LH-RH can be used for the treatment of some hormone-dependent tumors, such as prostatic and breast cancer (1, 2) . In view of many expected medical applications of LH-RH derivatives, more than 2000 analogs have been synthesized since the isolation and structural elucidation of LH-RH (3). Many agonistic analogs more potent than the parent hormone have been made (1, 2, 4) . Several of these agonists are being used clinically (1, 2, 5) . Potent inhibitory analogs of LH-RH, which block ovulation in laboratory animals, have also been synthesized (4) . Several antagonists of LH-RH have been tested in men and women and shown to be active enough for practical use (4) . LH-RH antagonists may offer certain advantages in the treatment of cancer as compared with the superagonists. While a repeated administration of LH-RH agonists is required to inhibit the pituitary and gonadal function and reduce the levels of sex steroids, the same effect may be obtained by a single administration of LH-RH antagonists (4) . The inhibition of gonadotropin release by LH-RH antagonists starts immediately after its administration, while the agonists cause a transient stimulation of pituitary and gonadal function, which may result in a temporary clinical "flare-up" of the disease (5) .
LH-RH antagonists are frequently characterized by the nature of the residue at position 6. Some potent LH-RH antagonists contained D-arginine (hydrophilic basic substitution) at this position. However, this class of analogs produced transient edema of the face and extremities when administered subcutaneously to rats (6, 7) . In preliminary human tolerance studies, side effects were also observed in some cases after administration of antagonists with basic D-amino acids at position 6. These reactions could be due to histamine liberation. These side effects delayed clinical use of LH-RH antagonists in humans.
To obtain LH-RH antagonists free of edematogenic effects, new analogs with D-ureidoalkyl amino acids, such as D-citrulline (D-Cit) and D-homocitrulline (D-Hci), at position 6 were synthesized and tested in several in vitro and in vivo systems (4 (9) .
In the present study, we evaluated the effects of two antagonists free of edematogenic effects: [Ac-D-Nal (2) 
MATERIALS AND METHODS
Peptides. Buserelin was a gift from J. Sandow (Hoechst), ORG 30276 was obtained from L. Tax (Organon), the antagonists SB-29 and SB-30 were synthesized and purified in the Veterans Administration/Tulane University laboratory as reported (4) . 
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Cells. MDA-MB-231 human mammary cancer cells were obtained from H. Rochefort (Institut National de la Santd et de la Recherche Mddicale, Montpellier, France). The cells were grown in 75-cm2 flasks in Dulbecco's modified Eagle's medium (Biological Industries, Beth Haemek, Israel) containing penicillin (100 units/ml), streptomycin (0.1 mg/ml), nystatin (12.5 units/ml), and 10%o (vol/vol) fetal calf serum.
[3lH]Thymidine Incorporation. Cells were seeded into 96-multiwell plates in 0.1 ml ofmedium. After 1 day, the medium was replaced with medium containing various concentrations of LH-RH analogs and changed daily. After 1 or 2 days of incubation, fresh medium was used containing [3H]thymidine (40 pkCi/ml; 1 ACi = 37 kBq), in addition to the peptides. The incorporation was stopped by addition of unlabeled thymidine (0.5 .tmol). The cells were washed twice with phosphatebuffered saline and three times with 10%o trichloroacetic acid to remove soluble thymidine and then were dissolved in 0.1 M NaOH. The basic solution was neutralized with 5% vol/vol acetic acid and assayed in Insta-Gel (Packard, Downers Grove, IL).
Cell Proliferation Experiments. Cells were seeded into 6-multiwell plates (4 x 104 cells per well) and grown for 1 day.
The medium was then replaced with fresh medium containing the LH-RH analogs and changed daily. At the times indicated, the cells were removed with trypsin and counted with a hemacytometer. (Fig. 3) . The growth inhibition was detectable from day 2 of exposure to antagonists and reached a maximal level of 84% on day 5 of treatment with 30 ,M SB-29. Although this is a high concentration, there was also a considerable inhibition at 10 ,uM (60%6) and 10 AtM (53%). The inhibition ofcell growth by SB-30 appeared to be smaller than that caused by SB-29. Since this difference was evident only on or after the third day of incubation, it is possible that the two compounds possess different stabilities in the incubation medium. The LH-RH agonist buserelin did not affect cell growth significantly (Fig. 4) , although a slight inhibition may occur after 6 days of incubation. incorporation. However, when one of these antagonists was tested in a cell-growth experiment, it proved to be much less effective and less potent in inhibiting cell proliferation (9) than the antagonists studied by us. The discrepancy between thymidine incorporation and cell growth in experiments by Eidne et al. (9) is not clear. For our studies, we used the hormone-independent human cell line MDA-MB-231. This line is characterized as estrogen unresponsive (14); thus, it may be a good model for testing the antagonists of LH-RH for their direct inhibitory effect, which must be clearly differentiated from the antitumor effects produced by the creation of the state of estrogen deficiency. The MDA-MB-231 line may be representative of many human mammary tumors. These "estrogen-independent" breast cancers are less responsive to various hormonal manipulations, are frequently more aggressive in nature (15) , and thus present a challenge for the development of drugs that might affect their growth. A direct effect of LH-RH analogs on estrogen-responsive 7,12-dimethylbenz[a]anthracene (DMBA)-induced mammary tumor in the rat has been demonstrated by us (16) . The DMBA-induced mammary carcinoma serves as a model for the human hormoneresponsive cancers, as its growth rate can be influenced by endocrine manipulations. Estrogens (17) and prolactin (18) stimulate the growth of DMBA tumors, while ovariectomy (17), antiestrogens (19) , and drugs that decrease plasma prolactin levels cause growth arrest or regression of these tumors (20) . Moreover, we have shown that hormonal transmembrane transducing mechanisms, such as tyrosine kinase activity (20) and the phosphatidylinositol cycle (21), may be involved in the growth control of DMBA tumors. A direct interaction of LH-RH analogs with DMBA tumor was shown by the enhancement of phospholipase C activity in the tumor membranes by LH-RH agonists and the inhibition of this activity by LH-RH antagonists (16) . Thus, there is a high probability that human sex-steroid-responsive mammary tumors would respond to treatment with LH-RH antagonists not only by virtue of estrogen deprivation but also through direct effects. Preliminary results with [3H]thymidine incorporation in the estrogen-responsive MCF-7 cells support the notion of direct effects. The inhibition of estrogen-dependent mammary tumors in mice and rats by administration of LH-RH antagonists, including ORG 30276, has been documented (22) .
RESULTS

Effect of Incubation
Our study shows that the new LH-RH antagonists with D-citrulline and D-homocitrulline at position 6 are better inhibitors of MDA-MB-231 mammary tumor cell proliferation than the 6-D-arginine-substituted antagonist ORG 30276 or the superagonist buserelin. In view of favorable clinical results with LH-RH agonists in the treatment of prostate cancer, mammary carcinomas, and ovarian cancer (1, 2), our results support the view that the new LH-RH antagonists also might be potentially useful for the therapy of these and other tumors.
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